Tenderwize
Retour à la recherche

Non-exclusive rebate agreement for Aclidiniumbromid

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 29, 2028 · 550 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Aclidiniumbromid (ATC-Code nach WHO: R03BB05)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The notice says participation documents must be submitted via the DTVP communication function, while also stating that...

Only the first participation deadline is explicitly stated in the extracted text; further deadlines are in a missing at...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Non-exclusive rebate agreements for pharmaceutical products containing Aclidiniumbromid (ATC R03BB05).
  • Open-House model: any interested eligible pharmaceutical company may join during the participation period.
Afficher le résumé complet

This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements under §130a(8) SGB V for the active substance Aclidiniumbromid (ATC R03BB05). The lead buyer is AOK PLUS. No contract value is stated; demand and minimum purchase volumes are explicitly not guaranteed. Participation is open to all eligible pharmaceutical companies during the participation period, with electronic communication via DTVP and no electronic submission via the bidder tool. The notice and XML contain some inconsistencies on dates and submission mechanics, but the core scope and Open-House nature are clear.

Risques

The notice says participation documents must be submitted via the DTVP communication function, while also stating that...

Only the first participation deadline is explicitly stated in the extracted text; further deadlines are in a missing at...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal products.

Eligibility

  • Submission of the completed declaration on the absence of exclusion grounds is required.

Administrative

  • The company must meet the participation requirements in the documents 'Anschreiben' and 'Erläuterungen der Vertragsbedingungen'.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for Aclidiniumbromid

Open-House supply lot for non-exclusive pharmaceutical rebate agreements for medicines containing Aclidiniumbromid (ATC R03BB05). Scope is limited to the named active substance; no exclusivity, no individual negotiations, and no guaranteed minimum purchase volume. Place of performance is Dresden, Germany, with performance covering Germany and the federal states of Saxony and Thuringia as stated in the XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Feb 2026 - Feb 2028

Catégorie

Pharmaceutical products

Date limite

Expired Feb 03, 2026

Détails de la procédure

Date de publication
23 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
862508-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30